

## Original Article

# Concurrent Chemoradiotherapy Using Cisplatin and 5-Fluorouracil Alone or with Paclitaxel Followed by Adjuvant Cisplatin and 5-Fluorouracil in Nasopharyngeal Carcinoma

Jen-Cheng Lee<sup>1</sup>, Yi-Shing Leu<sup>1,2,3\*</sup>, Jehn-Chuan Lee<sup>1</sup>, Yi-Fang Chang<sup>4</sup>, Min-Jer Huang<sup>4</sup>, Yu-Jen Chen<sup>5</sup>, Hong-Wen Chen<sup>5</sup>

<sup>1</sup>Department of Otolaryngology- Head & Neck Surgery, Mackay Memorial Hospital

<sup>2</sup>Mackay Medicine, Nursing and Management College

<sup>3</sup>National Defense Medical Center

<sup>4</sup>Department of Hematology, Mackay Memorial Hospital

<sup>5</sup>Department of Radiology Oncology, Mackay Memorial Hospital

### Abstract.

**Purpose:** The purpose of this study was to analyze the treatment outcome of patients with nasopharyngeal carcinoma (NPC) treated with concurrent chemoradiotherapy (CCRT) with or without paclitaxel.

**Materials and Methods:** Seventy-seven patients with NPC received treatment at Mackay Memorial Hospital from 2002 to 2004. All of patients were treated with CCRT. Sixty-seven patients received chemotherapy of cisplatin and 5-fluorouracil (PF arm), and 10 patients received chemotherapy of paclitaxel, cisplatin and 5-fluorouracil (TPF arm). All patients received adjuvant PF after CCRT. Kaplan-Meier estimates were calculated for the overall and disease-free survival rates. Log-rank test was used to determine significant difference between the two arms.

**Results:** With a median follow-up of 43 months, 5-year overall survival rates (OS) and disease-free survival rates (DFS) for all patients were 72% and 65%, respectively. The 5-year OS in the PF arm and TPF arm were 71% and 80%, respectively (P=0.65). The 5-year DFS in the PF arm and TPF arm were 64% and 70%, respectively (P=0.61). There was no statistically significant difference between these two arms. Locoregional recurrence was found in 2 patients after the completion of treatment, and distant metastasis was found in 4 patients.

**Conclusions:** Our study failed to demonstrate the benefit of adding paclitaxel in CCRT of NPC. Standard PF regimen incorporated into radiation is still the treatment of choice for NPC.

**Keywords :** nasopharyngeal carcinoma, concurrent chemoradiotherapy, paclitaxel

## 原著論文

### 單獨使用順鉑及有利癌或合併太平洋紫杉醇並同步放射治療對於鼻咽癌患者治療結果分析

李仁正<sup>1</sup> 呂宜興<sup>1,2,3\*</sup> 李振川<sup>1</sup> 張義芳<sup>4</sup> 黃明哲<sup>4</sup> 陳裕仁<sup>5</sup> 陳虹汶<sup>5</sup>

<sup>1</sup>馬偕紀念醫院 耳鼻喉科